Professional Documents
Culture Documents
aplicar el 1 de Enero
de 2018.
Cambios en
patología de mama
The decision to delay implementation of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual,
Eighth Edition to January 1, 2018 has provided the AJCC with an opportunity to take a careful look at the way it has
traditionally communicated cancer staging. Since the manual was published last fall, the AJCC has worked with the
surveillance community, the pathology community, and clinical decision support software developers to take a more
critical look at the content and make improvements and clarifications that will help everyone who uses this
information including the registrar, clinician, and the software developer.
As part of this effort, the AJCC decided to validate and update the Eighth Edition breast cancer staging system
using an additional year's worth of data from the National Cancer Database (NCDB). The AJCC Breast Expert
Panel has recommended providing two breast cancer Prognostic Stage tables based on further analysis of the
NCDB data.
The Clinical Prognostic Stage Group will be used to assign stage for all patients based on history, physical
examination, imaging studies, and relevant biopsies. The Pathological Prognostic Stage Group will be used to
assign stage for patients who have surgical resection as the initial treatment of their cancer before any systemic or
radiation therapy. The Breast Expert Panel also recommended clinical, pathological, and post-therapy data
elements that cancer registries should record.
As science continues to evolve, the AJCC is committed to validating and incorporating important updates and
communicating them transparently. We understand the burden that these changes place on those who
purchased the first printing of the manual. To this end, the entire breast cancer chapter of the manual will be
publically available on November 10th through the AJCC website, and replacement pages for all updates and
corrections made to the entire manual will be available in December 2017. Future printings of the Staging Manual
will include the updated breast chapter as well as other minor updates and corrections issued to
date.
1. Cambios y Aclaraciones a la T
2. Cambios y Aclaraciones a la N y M
E-cadherina
AJCC 8ªed. pp 604 ó pp36/97
LCIS ya no se incluye en la categoria pTis
• Lesions in which the LCIS cells show the cytological features of classic LCIS
(type A or B) but in which there is marked distention of involved spaces
with areas of comedo necrosis.
All lesions in these groups typically lack E-cadherin expression and display
genomic alterations typical of lobular lesions (16q losses and 1q gains)
E-cadherina
LCIS ya no se incluye en la categoria pTis
• EXCISIÓN
• 40-50% upgraded
• pTis (CDIS).
Recomendaciones medición
www.cap.org
AJCC 8ºed. pp604
Cambio en la categoría T
4,9 mm = 5 mm
2,04 cm = 2 cm pT1c 2,06=2,1 pT2
• Todos los tumores que midan entre 1,1 y 1,4 mm, se redondean
hasta 2 mm para evitar clasificar tumores que miden entre 1,1 y
1,4 mm como microinfiltrantes.
• > 1 mm=pT1a
• Tumor de 16 mm en RX.
Correlación Rx
2. Cambios y Aclaraciones a la N y M
Ejemplos e Implicaciones
Categoria N: aclaraciones
• Nidos de tumor infiltrante en grasa axilar, sin presencia de
ganglio residual se considera ganglio afecto.
• Operada: pT, pN
Categoria N: aclaraciones
Para valorar la afectación neoplásica se cuenta el foco
continuo de mayor tamaño, no el área total de la afectación.
Macrometástasis Micrometástais ITC
Ganglio
centinela
< 0,2 mm
Biopsia líquida.
Decir qué técnica
hemos usado
2. Cambios y Aclaraciones a la N y M
Ejemplos e Implicaciones
Aclaraciones en la Neoadyuvancia: ypT, ypN
ypT:
•Foco contiguo de mayor tamaño sin áreas fibrosas (ypT).
ypN
•Para la N: foco celular contiguo de mayor tamaño.
Zona de fibrosis
respuesta.
Aclaraciones en la Neoadyuvancia
AJCC 8ªed. pp609-610 Keam et al. Ann Surg Oncol 2013; 20: 2242-2249
Aclaraciones en la Neoadyuvancia
Mencionado en la revisión del capítulo de mama
Zona de fibrosis
respuesta.
Número de ganglios positivos
y diámetro mayor
Aclaraciones en la Neoadyuvancia
2. Cambios y Aclaraciones a la N y M
Ejemplos e Implicaciones
Estadio grupo pronóstico
• Grado histológico
• Resultado de biomarcadores (estrógenos,
progesterona y HER2)
• Resultado de plataformas multigenes.
Estadio grupo
pronóstico
3728
QX
Grade
ILV
RE
RP
HER2
Estadio Anatómico.
Grado 3, ER-,HER2 -
Estadio Anatómico
Grado 1-2, ER+,HER2 +
AJCC 8ªed pp 77 de 96
Estadio grupo pronóstico
Pacientes con:
•ER/PR Positivos, HER2 Negativo y N0
•Tamaño ≤5 cm
•Combinado con cualquiera de las plataformas:
•OncotypeDx® recurrence score < 11 (nivel de evidencia I)
•Mamaprint ® low risk score
•Endopredict ® low risk score
•PAM50 ® risk recurrence score in low range
•Breast Cancer indez in low range.